WuXi AppTec acquires US-based CRO noting recent Chinese regulatory reforms

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/psisa)
(Image: Getty/psisa)

Related tags: Wuxi apptec, Clinical trial

WuXi AppTec’s acquisition of ResearchPoint Global (RPG) follows the release of a new guideline that will enable Chinese companies to accept clinical trial data from other countries.

The guideline was issued last week​ in a move to reform the management of clinical trials in the country.

WuXi cited the recent regulatory changes in its announcement of the acquisition, noting the opportunities presented by the reform.

According to the company, the acquisition is a strategic step forward to expand its clinical research capabilities in the US and globally.

The Austin, Texas-headquartered contract clinical research organization will operate as a wholly-owned subsidiary of WuXi. WuXi’s China-based Clinical Development Service (CDS) team will be integrated into the new business unit.

Dr. Ge Li WuXi AppTec chairman and CEO commented in a press release: "This business combination lays the groundwork for the creation of an integrated global clinical service organization with global expertise and global network."

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars